Oxyguanidines: Application to Non-peptidic Phenyl-based Thrombin Inhibitors
Overview
Authors
Affiliations
Although thrombin has been extensively researched with many examples of potent and selective inhibitors, the key characteristics of oral bioavailability and long half-life have been elusive. We report here a novel series non-peptidic phenyl-based, highly potent, highly selective and orally bioavailable thrombin inhibitors using oxyguanidines as guanidine-mimetics.
Development and Prospects of Furin Inhibitors for Therapeutic Applications.
Ivachtchenko A, Khvat A, Shkil D Int J Mol Sci. 2024; 25(17).
PMID: 39273149 PMC: 11394684. DOI: 10.3390/ijms25179199.
Lam van T, Heindl M, Schlutt C, Bottcher-Friebertshauser E, Bartenschlager R, Klebe G ACS Med Chem Lett. 2021; 12(3):426-432.
PMID: 33732412 PMC: 7957917. DOI: 10.1021/acsmedchemlett.0c00651.
Jones B, Tochowicz A, Tang Y, Cameron M, McCall L, Hirata K ACS Med Chem Lett. 2016; 7(1):77-82.
PMID: 26819670 PMC: 4716606. DOI: 10.1021/acsmedchemlett.5b00336.
Mena-Ulecia K, Tiznado W, Caballero J PLoS One. 2015; 10(11):e0142774.
PMID: 26599107 PMC: 4657979. DOI: 10.1371/journal.pone.0142774.
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases.
He L, Dai W, Li N Molecules. 2015; 20(6):11046-62.
PMID: 26083038 PMC: 6272601. DOI: 10.3390/molecules200611046.